Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone

Free Abstracts

  Malignant Melanoma

  Free Subscription


1 Anticancer Res
1 Biochem Biophys Res Commun
2 BMC Cancer
2 Br J Dermatol
2 Cancer
2 Cancer Lett
1 Clin Cancer Res
1 Clin Exp Metastasis
1 J Am Acad Dermatol
1 J Clin Oncol
1 J Invest Dermatol
2 Lancet
1 Melanoma Res
1 Oncogene
1 Ophthalmology
2 PLoS One
1 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Anticancer Res

  1. TANAKA T, Fujita M, Hasegawa H, Arimoto A, et al
    Frequency of Myeloid-derived Suppressor Cells in the Peripheral Blood Reflects the Status of Tumor Recurrence.
    Anticancer Res. 2017;37:3863-3869.
    PubMed     Text format     Abstract available

    Biochem Biophys Res Commun

  2. WANG S, Tang L, Lin J, Shen Z, et al
    ABCB5 promotes melanoma metastasis through enhancing NF-kappaB p65 protein stability.
    Biochem Biophys Res Commun. 2017 Aug 15. pii: S0006-291X(17)31604.
    PubMed     Text format     Abstract available

    BMC Cancer

  3. HARRER DC, Simon B, Fujii SI, Shimizu K, et al
    RNA-transfection of gamma/delta T cells with a chimeric antigen receptor or an alpha/beta T-cell receptor: a safer alternative to genetically engineered alpha/beta T cells for the immunotherapy of melanoma.
    BMC Cancer. 2017;17:551.
    PubMed     Text format     Abstract available

  4. DE SMEDT J, Van Kelst S, Boecxstaens V, Stas M, et al
    Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial.
    BMC Cancer. 2017;17:562.
    PubMed     Text format     Abstract available

    Br J Dermatol

  5. HILL D, Lovat P
    Cover Image: Invasion of a cutaneous melanoma tumour.
    Br J Dermatol. 2017;177:599.
    PubMed     Text format    

  6. BERK-KRAUSS J, Stein JA
    The role of access to care in acral lentiginous melanoma survival.
    Br J Dermatol. 2017;177:341-342.
    PubMed     Text format    


  7. BARUCH EN, Berg AL, Besser MJ, Schachter J, et al
    Adoptive T cell therapy: An overview of obstacles and opportunities.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available

  8. JOHNSON DB, Sullivan RJ, Menzies AM
    Immune checkpoint inhibitors in challenging populations.
    Cancer. 2017;123:1904-1911.
    PubMed     Text format     Abstract available

    Cancer Lett

  9. CIMAS FJ, Callejas-Valera JL, Garcia-Olmo DC, Hernandez-Losa J, et al
    E1a is an exogenous in vivo tumour suppressor.
    Cancer Lett. 2017;399:74-81.
    PubMed     Text format     Abstract available

  10. RUZZOLINI J, Peppicelli S, Andreucci E, Bianchini F, et al
    Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH.
    Cancer Lett. 2017 Aug 18. pii: S0304-3835(17)30487.
    PubMed     Text format     Abstract available

    Clin Cancer Res

  11. KONG Y, Sheng X, Wu X, Yan J, et al
    Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma indicate the potential for CDK4/6 Inhibitors in Targeted Therapy.
    Clin Cancer Res. 2017 Aug 22. pii: clincanres.0070.2017.
    PubMed     Text format     Abstract available

    Clin Exp Metastasis

  12. VENKATESHAIAH SU, Eswaraiah MS, Annaiah HN, Dharmesh SM, et al
    Antimetastatic pectic polysaccharide from Decalepis hamiltonii; galectin-3 inhibition and immune-modulation.
    Clin Exp Metastasis. 2017;34:141-154.
    PubMed     Text format     Abstract available

    J Am Acad Dermatol

  13. HELGADOTTIR H, Tuominen R, Olsson H, Hansson J, et al
    Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.
    J Am Acad Dermatol. 2017 Aug 14. pii: S0190-9622(17)31806.
    PubMed     Text format     Abstract available

    J Clin Oncol

  14. SCHADENDORF D, Wolchok JD, Hodi FS, Chiarion-Sileni V, et al
    Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
    J Clin Oncol. 2017 Aug 25:JCO2017732289. doi: 10.1200/JCO.2017.73.2289.
    PubMed     Text format     Abstract available

    J Invest Dermatol

  15. TAYLOR NJ, Mitra N, Goldstein AM, Tucker MA, et al
    Germline variation at CDKN2A and associations with nevus phenotypes among members of melanoma families.
    J Invest Dermatol. 2017 Aug 19. pii: S0022-202X(17)32759.
    PubMed     Text format     Abstract available


    KEYNOTE-006: a success in melanoma, but a long way to go.
    Lancet. 2017 Aug 16. pii: S0140-6736(17)31816.
    PubMed     Text format    

  17. SCHACHTER J, Ribas A, Long GV, Arance A, et al
    Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Lancet. 2017 Aug 16. pii: S0140-6736(17)31601.
    PubMed     Text format     Abstract available

    Melanoma Res

  18. TARHINI AA, Floros T, Lin HM, Lin Y, et al
    A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma.
    Melanoma Res. 2017 Aug 18. doi: 10.1097/CMR.0000000000000383.
    PubMed     Text format     Abstract available


  19. LECLERC J, Ballotti R, Bertolotto C
    Pathways from senescence to melanoma: focus on MITF sumoylation.
    Oncogene. 2017 Aug 21. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  20. SZALAI E, Wells JR, Ward L, Grossniklaus HE, et al
    Uveal Melanoma Nuclear BRCA1-Associated Protein-1 Immunoreactivity Is an Indicator of Metastasis.
    Ophthalmology. 2017 Aug 17. pii: S0161-6420(17)31332.
    PubMed     Text format     Abstract available

    PLoS One

  21. CHEN J, Peng C, Lei L, Zhang J, et al
    Nuclear envelope-distributed CD147 interacts with and inhibits the transcriptional function of RING1 and promotes melanoma cell motility.
    PLoS One. 2017;12:e0183689.
    PubMed     Text format     Abstract available

  22. ZALESNA I, Osrodek M, Hartman ML, Rozanski M, et al
    Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro.
    PLoS One. 2017;12:e0183498.
    PubMed     Text format     Abstract available

    Proc Natl Acad Sci U S A

  23. DUGGAN MC, Stiff AR, Bainazar M, Regan K, et al
    Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.
    Proc Natl Acad Sci U S A. 2017 Aug 21. pii: 201704371.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.